- No immediate impact on listing of loanDepot’s Class A common stock or business operations
- Company intends to cure the deficiency and return to compliance with the NYSE listing standard
loanDepot, Inc. (NYSE:LDI) (together with its subsidiaries, “loanDepot”) today announced that on August 21, 2026, it received a deficiency letter from the New York Stock Exchange (the “NYSE”) notifying loanDepot that it is not in compliance with applicable price criteria in the NYSE’s continued listing standards.
This notice has no immediate impact on the ability of loanDepot’s Class A common stock to continue to trade on the NYSE during the cure period. Furthermore, there is no immediate impact on the ongoing business operations of loanDepot or its reporting requirements with the U.S. Securities and Exchange Commission.
The notice was received because as of August 20, 2026, the average closing price of loanDepot’s Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period (the “Notice”).
loanDepot will respond to the NYSE within ten business days of receipt of the notice of its intent to cure the deficiency. Pursuant to the applicable NYSE rules, loanDepot has a six-month period following receipt of the Notice to bring its share price and average share price back above $1.00. LoanDepot will consider available alternatives to cure the stock price non-compliance, including, if necessary, a reverse stock split that would be subject to stockholder approval no later than at loanDepot’s next annual meeting of stockholders anticipated for early June 2027.